Recent Recurrent Melanoma News

Pembrolizumab Gets FDA Approval in Advanced Melanoma (September 5, 2014)

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug,... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1]... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the... Continue Reading

FDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma (January 24, 2014)

The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new diagnoses... Continue Reading

Yervoy Shows Long-Term Survival Advantage in Advanced Melanoma (October 23, 2013)

Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the European... Continue Reading

Tafinlar Shows Promise in BRAF-600E/K Mutant Metastatic Melanoma (August 28, 2013)

The targeted agent Tafinlar® (dabrafenib) produced a high response rate in patients with metastatic melanoma with a BRAF-V600E mutation, according to the results of a study published in the Journal of... Continue Reading

Next Page »